Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:INSM News 18 December 2025 - 2 January 2026

Liquidia stock drops 8% today as put-option hedging spikes — what’s next for LQDANEW YORK, Jan 2, 2026, 14:24 ET — Regular session

Liquidia stock drops 8% today as put-option hedging spikes — what’s next for LQDANEW YORK, Jan 2, 2026, 14:24 ET — Regular session

Liquidia Corp shares slid about 8% in afternoon trade on Friday, giving back earlier gains and underperforming the broader biotech group. The stock was down $2.79 at $31.70, after trading between $30.76 and $34.97. Volume topped 1.88 million shares. The move matters because Liquidia has become a high-volatility bet on sales of Yutrepia, its inhaled treprostinil therapy for pulmonary hypertension. On its Nov. 3 earnings call, the company said third-quarter net product sales were $51.7 million, and chief operating officer and CFO Michael Kaseta told investors, “We expect this positive trend to extend into 2026.” Investing Liquidia entered 2026 after
2 January 2026
·······
Insmed (INSM) Stock After Hours Today (Dec. 22, 2025): Closing Price, Nasdaq-100 Effect, Fresh Forecasts, and What to Watch Before Tuesday’s Open

Insmed (INSM) Stock After Hours Today (Dec. 22, 2025): Closing Price, Nasdaq-100 Effect, Fresh Forecasts, and What to Watch Before Tuesday’s Open

Insmed Incorporated (NASDAQ: INSM) ended Monday’s session slightly higher and then traded in a tight range after the closing bell, as investors weighed two forces that have been shaping the stock into year-end: Nasdaq-100 inclusion (effective today) and the market’s continuing digestion of last week’s brensocatib CRSsNP trial miss. StockAnalysis+2Mondo Visione+2 Below is what happened after the bell on Dec. 22, 2025, and the key items to know before U.S. markets open Tuesday, Dec. 23, 2025. INSM stock price after the bell: where shares finished and what after-hours trading showed Insmed closed regular trading on Monday, Dec. 22 at $175.76,
23 December 2025
····
Insmed (INSM) Stock News Today: Nasdaq‑100 Addition, Brensocatib Setback, and Updated Analyst Forecasts (Dec. 22, 2025)

Insmed (INSM) Stock News Today: Nasdaq‑100 Addition, Brensocatib Setback, and Updated Analyst Forecasts (Dec. 22, 2025)

Insmed Incorporated (NASDAQ: INSM) is ending 2025 with two headlines pulling the stock in opposite directions: fresh visibility from joining the Nasdaq‑100 Index and fresh volatility after a clinical disappointment for a key expansion effort. As of Monday, December 22, 2025 (17:56 UTC), INSM traded at $177.86, up about $3.02 (~1.7%) on the day, after swinging sharply in recent sessions. Below is what’s moving Insmed stock now, what Wall Street is forecasting after the latest developments, and the pipeline and financial checkpoints investors are watching into 2026. What’s driving Insmed stock on Dec. 22, 2025 1) Insmed officially joins the
22 December 2025
····
Insmed (INSM) Stock: What to Know Before the Market Opens on Dec. 22, 2025

Insmed (INSM) Stock: What to Know Before the Market Opens on Dec. 22, 2025

Insmed Incorporated (NASDAQ: INSM) heads into the Monday, Dec. 22, 2025 session with two powerful—almost opposing—forces in play: a fresh clinical disappointment that jolted sentiment last week, and a major index catalyst that can drive mechanical buying at the open. Shares last closed at $174.84 (up about 5% on the day) after an exceptionally volatile week for the biotech, with after-hours trading roughly flat. StockAnalysis Below is what investors and traders typically want on their radar before the bell. The biggest catalyst for Monday: Insmed joins the Nasdaq-100 before the open Insmed is scheduled to be added to the Nasdaq-100
22 December 2025
·····
Insmed Incorporated (NASDAQ: INSM) Stock Week Ahead: Nasdaq-100 Addition Meets Brensocatib Setback—News, Forecasts, and What to Watch (Dec. 22–26, 2025)

Insmed Incorporated (NASDAQ: INSM) Stock Week Ahead: Nasdaq-100 Addition Meets Brensocatib Setback—News, Forecasts, and What to Watch (Dec. 22–26, 2025)

As of Sunday, December 21, 2025, Insmed Incorporated (NASDAQ: INSM) is heading into a pivotal (and holiday-shortened) trading week with two narratives pulling on sentiment at the same time: That push-pull dynamic is likely to define the week-ahead setup for INSM as markets reopen Monday. INSM stock snapshot heading into the week (as of Dec. 21, 2025) Because this coming week includes Christmas holiday trading conditions, liquidity can be thinner than normal—sometimes amplifying both index-related moves and any lingering “headline drift” from last week’s biotech news. The headline that sparked the volatility: brensocatib CRSsNP Phase 2b miss What happened On
21 December 2025
···
Insmed (INSM) Stock News and Forecasts on Dec. 20, 2025: Brinsupri Trial Miss, Truist Upgrade, and Updated Price Targets

Insmed (INSM) Stock News and Forecasts on Dec. 20, 2025: Brinsupri Trial Miss, Truist Upgrade, and Updated Price Targets

December 20, 2025 — Insmed Incorporated (NASDAQ: INSM) is ending the week in “re-pricing mode” after a mid-stage clinical setback jolted investor expectations, sparked sharp volatility, and triggered a round of analyst price-target revisions. By Friday’s close (the last U.S. trading session before today’s Saturday), Insmed shares finished at $174.84, up about 5% on the day—recovering some ground after Thursday’s steep drop. The catalyst remains the same: Insmed disclosed that its Phase 2b BiRCh study of brensocatib (brand: Brinsupri) in chronic rhinosinusitis without nasal polyps (CRSsNP)missed both primary and secondary efficacy endpoints, prompting the company to discontinue that indication. At
20 December 2025
····
Insmed (INSM) Stock After Hours on Dec. 19, 2025: Friday Rebound Holds, Analyst Targets Reset, and What to Watch Before the Next Market Open

Insmed (INSM) Stock After Hours on Dec. 19, 2025: Friday Rebound Holds, Analyst Targets Reset, and What to Watch Before the Next Market Open

Insmed Incorporated (NASDAQ: INSM) closed out a turbulent week with a sharp rebound on Friday, Dec. 19, 2025, and the move largely held after the bell—a sign that investors may be trying to stabilize expectations after the company’s latest clinical update whipsawed the stock earlier in the week. By the end of Friday’s regular session, INSM finished at about $174.84, up ~4.97% on the day. In after-hours trading, shares were roughly flat around $174.85 as of early evening, suggesting no new material catalyst hit the tape late Friday. MarketWatch One important calendar note: Dec. 20, 2025 is a Saturday, so
20 December 2025
·····
Insmed Stock (INSM) Rebounds on Dec. 19, 2025 After BiRCh Trial Miss: Latest News, Analyst Forecasts, and What Comes Next

Insmed Stock (INSM) Rebounds on Dec. 19, 2025 After BiRCh Trial Miss: Latest News, Analyst Forecasts, and What Comes Next

December 19, 2025 — Insmed Incorporated (NASDAQ: INSM) is back in focus today after a sharp, news-driven selloff on Thursday and a noticeable bounce on Friday. As of 15:46 UTC on Dec. 19, INSM shares were trading around $174.90, up roughly $8.35 (+5.0%) versus the prior close, with the day’s range spanning about $166.01 to $174.90. That rebound follows a steep Thursday decline after Insmed reported that its Phase 2b BiRCh trial of brensocatib (brand: Brinsupri) in chronic rhinosinusitis without nasal polyps (CRSsNP) missed endpoints, leading the company to discontinue development in that indication. Insmed Incorporated Investor Relations+1 What’s driving
19 December 2025
·····
Insmed Stock (NASDAQ: INSM) Slides on Brensocatib Sinus-Trial Failure; Analysts Reset Forecasts

Insmed Stock (NASDAQ: INSM) Slides on Brensocatib Sinus-Trial Failure; Analysts Reset Forecasts

December 18, 2025 — Insmed Incorporated (NASDAQ: INSM) shares dropped sharply Thursday after the company disclosed a Phase 2b setback for brensocatib in a chronic sinus condition and said it is discontinuing development in that indication, even as it simultaneously added a new Phase 2–ready antibody to its pipeline. SEC+1 Insmed stock was trading around $166.75 in the afternoon snapshot available from market data, down about 16% on the day, after touching an intraday low of $158.06 and high of $173.99. What happened to INSM stock on December 18, 2025 The selloff traces back to Insmed’s disclosure that its Phase
18 December 2025
·····

Stock Market Today

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop